Shares of Pfizer rise after the company announces positive results in a late-stage, non-steroid trial of a treatment for chronic dermatitis, or eczema, in kids.
The firm now has a neutral rating on Biogen based on data from a new neurologist survey.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Acer plummets toward a record low after the Food and Drug Administration declined to approve its treatment for a genetic disorder that can cause blood vessels to fatally rupture.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.